<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499485</url>
  </required_header>
  <id_info>
    <org_study_id>TRAMA study</org_study_id>
    <nct_id>NCT01499485</nct_id>
  </id_info>
  <brief_title>Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.</brief_title>
  <acronym>TRAMA</acronym>
  <official_title>Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Son Llatzer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Son Llatzer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze whether the treatment of metabolic alkalosis with
      acetazolamide in intubated patients with chronic obstructive pulmonary disease (COPD) or with
      obesity hypoventilation syndrome (OHS) reduces the length of mechanical ventilation (MV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic alkalosis (MA) may reduce central respiratory drive, cardiac output and worsen
      oxygenation, leading to a delay in weaning from MV. Acetazolamide is a carbonic anhydrase
      inhibitor that is able to correct MA and to stimulate respiratory drive. There is a paucity
      of studies on the outcome of patients with MA under MV treated with acetazolamide.

      The primary objective of our study is to analyze whether the treatment of MA with
      acetazolamide in intubated patients with COPD or with OHS reduces the length of MV, reduces
      the length of ICU stay or ICU mortality. Complications associated with acetazolamide
      treatment will be also analyzed.

      Phase III double-blinded trial, with COPD or OHS patients under MV who have pH &gt; 7,35 and
      bicarbonate &gt; 28 mEq/L. Patients will be randomized to receive 500 mg of acetazolamide or
      placebo. According to arterial blood gas analysis (ABGA) values treatment administration will
      be evaluated daily until extubation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>From intubation date to extubation date, an expected average of 1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of intensive care unit stay</measure>
    <time_frame>The duration of ICU stay, an expected average less than 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospital mortality</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>Alive or dead status will be recorded at the end of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications associated to the treatment</measure>
    <time_frame>During the mechanical ventilation period, an expected average of 1 week</time_frame>
    <description>Plasma and urine analysis will be performed to detect alteration in electrolites or renal function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <condition>Metabolic Alkalosis</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Daily morning ABGA:
If actual bicarbonate &gt; 26 mmol/L and pH &gt; 7.35: administration of enteral capsule of acetazolamide 500 mg .
If actual bicarbonate &gt; 26 mmol/L and pH &lt;= 7.35, increase minute ventilation to reach pH &gt; 7.35 and then administer enteral capsule of acetazolamide 500 mg.
If actual bicarbonate &lt;= 26 mmol/L: omit treatment that day.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Edemox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily morning ABGA:
If actual bicarbonate &gt; 26 mmol/L and pH &gt; 7.35: administration of enteral capsule of placebo.
If actual bicarbonate &gt; 26 mmol/L and pH &lt;= 7.35, increase minute ventilation to reach pH &gt; 7.35 and then administer enteral capsule of placebo.
If actual bicarbonate &lt;= 26 mmol/L: omit treatment that day.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with COPD or obesity hypoventilation syndrome on invasive mechanical
             ventilation during less than 72 h with metabolic alkalosis, defined as a pH &gt; 7.35 and
             actual bicarbonate &gt; 28 mmol/L, and with potassium plasmatic levels &gt;= 4 mEq/L.

        Exclusion Criteria:

          -  Postoperative patients.

          -  Previous psychiatric disease.

          -  Epilepsy.

          -  Pregnancy.

          -  Hepatic cirrhosis.

          -  Sulfonamide or acetazolamide allergy.

          -  Plasmatic creatinine &gt; 2.5 mg/dL or creatinine clearance &lt; 20 mL/min or continuous
             renal replacement techniques.

          -  Intolerance to enteral feeding.

          -  Administration in the previous 72 h of bicarbonate or acetazolamide.

          -  Terminal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fundació Hospital Asil de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad de Madrid</state>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad de Madrid</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manacor</name>
      <address>
        <city>Manacor</city>
        <state>Illes Balears</state>
        <zip>07500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Faisy C, Mokline A, Sanchez O, Tadié JM, Fagon JY. Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation. Intensive Care Med. 2010 May;36(5):859-63. doi: 10.1007/s00134-010-1795-7. Epub 2010 Mar 9.</citation>
    <PMID>20217045</PMID>
  </reference>
  <reference>
    <citation>Raurich JM, Rialp G, Ibáñez J, Llompart-Pou JA, Ayestarán I. Hypercapnic respiratory failure in obesity-hypoventilation syndrome: CO₂ response and acetazolamide treatment effects. Respir Care. 2010 Nov;55(11):1442-8.</citation>
    <PMID>20979670</PMID>
  </reference>
  <reference>
    <citation>Mazur JE, Devlin JW, Peters MJ, Jankowski MA, Iannuzzi MC, Zarowitz BJ. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med. 1999 Jul;27(7):1257-61.</citation>
    <PMID>10446816</PMID>
  </reference>
  <reference>
    <citation>Banga A, Khilnani GC. Post-hypercapnic alkalosis is associated with ventilator dependence and increased ICU stay. COPD. 2009 Dec;6(6):437-40. doi: 10.3109/15412550903341448.</citation>
    <PMID>19938966</PMID>
  </reference>
  <reference>
    <citation>Moviat M, Pickkers P, van der Voort PH, van der Hoeven JG. Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients. Crit Care. 2006 Feb;10(1):R14.</citation>
    <PMID>16420662</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Son Llatzer</investigator_affiliation>
    <investigator_full_name>Gemma Rialp</investigator_full_name>
    <investigator_title>MD; PhD</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>Obesity Hypoventilation Syndrome</keyword>
  <keyword>Alkalosis</keyword>
  <keyword>Respiration, Artificial</keyword>
  <keyword>Acetazolamide</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
    <mesh_term>Alkalosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

